HGH-CTP

jakemn lookingforatenbagger dnr08 c2crusher

If I'm reading these posts correctly regarding ASND, it appears I am not alone in being ASTOUNDED at where ASND trades. Astounded understates it. It is completely unfathomable to me that a company with zero revenues and zero operating history can trade at this valuation. I also cannot believe how many analysts, who are smarter than this, are buying into the "superior than" vs. "just as good as" indications when it is a matter of centimeters, which is irrelevant and is only "superior" b/c ASND superdosed with HgH which increased the risk profile as well. Analyst and investors should also know that generally the insurance companies, NOT the customer, decides which one they get, and ASND has to compete against Pfizer, who, by the way, already sells this product, is already in all the offices, will get better rates from insurance companies b/c of size and can also bundle this to keep ASND out - why does this logic that applies to every other company, but just vanish in ASND analysis? In fact, ASND's greatest advantage, other than their tremendous execution in beating us for approval dates, is their delivery system which is rarely mentioned and again since customers don't have complete say in the product is less relevant. Even more, our pdufa date is Oct and ASND's is June. For those who are a little more knowledgeable in the space, there is a very good chance we are approved closer to June than October as the FDA usually will just put two similar products like these together: the pdufa date is an outside date, not the only date. But even that aside...who cares about 4 months - patients turnover ever 3 years and it is PFIZER. And at the risk of icemandios wrath for writing more than 4 sentences because he holds his breath while reading for some reason, we have heard OPK (and every other company) discuss Rayaldee and routine sales are down bc sales people can't physically get into offices until COVID-19 risks die down. How does one venture ASND sales reps will get into offices? While more may be open come July, its not 100% or anywhere near it, esp with telemedicine and if there is any sort of further spike. So if Quest and Labcorp and other pharma companies can't get reps into offices...how is ASND going to do it? And if they can't...how do they sell a single product? I am nothing short of flabbergasted and I would welcome any criticism of my analysis or what I am missing. Also, all the analysts in the notes mentioned in previous posts use a ~$3.5b TAM and ASND stated it was $4bn yesterday, which no matter what one thinks would increase OPK's value.

And on this topic, ASND valuation aside, ASND has been getting credit for years; and definitely for the year prior to the pdufa date, and we are somehow getting none. We also will have a monopoly in Japan and filed faster than guided in europe (1q vs 1h guide). INFURIATING.

I probably should start a new post on this new topic, but it relates to this only in my frustration level. Another stock I have been doing research on is Fulgent. They are the other lab with NYC DoE testing - BRL isn't exclusive, meaning FLGT has the same claim to the largest school system as BRL. But FLGT has also announced, in just the past 4 weeks, that they won additional contracts in "multiple schools and municipalities" (for example, they won Clark County in Las Vegas and San Mateo County in CA) and pointed to retaining the NYC Public Schools System business through the 2021 school year as demonstrating that Fulgent can meet the stringent needs of this very large school system while also seamlessly winning new business and executing on that and proving they can win the "school system expertise argument". Fulgent also announced they have signed agreements with multiple cruise lines, corporations, nursing homes, assisted living facilities and "among others". Twisting the knife further, in this same previous 4 week period, they announced they were one of four selected by the Dept of Homeland security for testing, a $2 BILLION dollar contract (partnered with Fed Resources) with years options to renew. And I previously mentioned their >90% genetic testing 2021 growth vs OPK's "proud to announce GeneDx is back to 2019 levels" - EVEN WITH PARTNERING with the largest NICU practice with Mednax in the August deal which did not exist in 2019 (also, the westchester hospital contract and its 7mm tests, as well as their 2 announced texas wins w/ the hospital and the nursing homes, and the many other unannounced wins). The more I research the company the angrier I get at OPK. I should probably post the FLGT stuff elsewhere - if so, can one of the veterans let me know where or do i do another thread? Or maybe its not useful to anyone -- which is fine....in which cases leave it be and sorry if it wasn't helpful.

If folks do find it useful, I'd also be interested in others opinions on another piece I struggle with and that the Company cannot answer either. I'd like to start a thread on what I'm doing wrong in reconciling their numbers - specifically, they are exclusive with Rite Aid's 1200 stores which have capacity of >100/store, increased testing to include children raising the TAM some months back, and averages ~18 tests a day per location. CVS has 10x the locations and more traffic per store, but BRL isn't exclusive, so if assume they get just 10% of the business - i.e. if we just assume its another rite aid, those two combine to 44k tests/day. They said on the call they are doing 50k-60k/day. But on top of those 44k tests, they have college contracts, municipality contracts (townships in nj or ny, etc), the NYC DOE contract, the NY MTA contract (50k employees), TONS of hospital business, TONS of nursing home business, MILLIONS of tests from the sports contracts, and lets not forget 200 patient service centers which do >100 test per day (they don't break down how many are covid...but it does not seem unreasonable to assume that if their own PATIENT SERVICE CENTER was as good as a rite aid drive thru, it would add 3500 tests a day. This doesn't even include things like Cohen saying "the midwest states are at capacity so they are calling to give us the overflow" on the November '20 call, urgent care centers, the employers they claim to have signed up but haven't disclosed, etc. I have more to say, but even I know I've gone on too long. Thanks for letting me vent a bit. And I'd welcome thoughts on where my analysis is materially wrong (please refrain from immaterial points that don't change the conclusion I'm drawing. And I am assuming I'm wrong, since I haven't seen these things said anywhere, the analysts (included those mentioned in the post above) have not been able to answer the question, and neither has the Company's useless IR (fun fact: OPK, I believe, is the largest company to use an external IR in the country - a fact short sellers usually note as them wanting plausible deniability vs. having someone knowledgeable).